Search
This study investigates the different patterns of relapse in patients with central nervous system mixed malignant germ cell tumors - treated with chemotherapy.
Co-Head, Brain Tumour Research
Head of Paediatric and Adolescent Oncology and Haematology, Perth Children’s Hospital; Co-head, Brain Tumour Research Program, The Kids Research Institute Australia
The Kids Research Institute Australia researcher, Dr Raelene Endersby, will work to develop less toxic treatments for children with brain cancer, thanks to support from Cancer Council WA.
A new combination of drugs could help to increase survival rates with fewer side effects for some children with one of the most aggressive forms of childhood brain cancer.
Tissue resident memory T cells are cancer killing immune cells that have emerged as key players in immune-mediated control of solid cancers, as well as being markers of prognosis and predictors of response to immunotherapy.
This study investigated the relapse and outcome patterns of patients with central nervous system mixed malignant germ cell tumors treated with chemotherapy-only
Medulloblastoma, the most common pediatric malignant brain tumor, consists of at least four distinct molecular subgroups.
Rare childhood cancers have not benefited to the same extent from the gains that have been made for their frequently occurring counterparts.
Medulloblastoma is the most common form of malignant paediatric brain tumour and is the leading cause of childhood cancer related mortality.